What Индоксил treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains that involve localized management of acne vulgaris, a condition presenting with symptomatic manifestations in adolescents and adults aged 12 years and older. It is generally applied in conditions characterized by periods of heightened symptoms associated with mild to moderate disease severity, including moderately severe papulo-pustular forms.

---

This topical treatment is relevant for easing symptoms that interfere with daily comfort, encompassing inflammatory lesions (papules and pustules) and non-inflammatory blemishes (blackheads and whiteheads). In clinical settings, the medication is commonly used to help with the management of chronic, symptomatic skin issues.

Therapeutic Focus This treatment is applied in scenarios where additional management of skin manifestations may be appropriate, playing a role in managing symptoms related to both active redness and tenderness, and underlying follicular blockage. It provides supportive relief that contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. FDA DailyMed for Clindamycin and Benzoyl Peroxide Gel

Индоксил, which contains the active ingredients Indomethacin (a non-steroidal anti-inflammatory drug, or NSAID) and Probenecid (a uricosuric agent), is generally used for specific types of inflammatory conditions, such as certain forms of arthritis. The combination is primarily intended for adults, but specific patient health factors and concurrent medications determine safe use.

---

Who Can Use Индоксил?

This medication is typically prescribed for patients with conditions like rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute gouty arthritis that require both the anti-inflammatory and pain-relieving effects of Indomethacin and the effect of Probenecid, which can increase Indomethacin levels and aid in uric acid excretion.

---

Who Cannot Use Индоксил? (Contraindications)

Use of Индоксил is not recommended or is strictly contraindicated for certain individuals due to the risk of serious side effects. These include patients with:

• Allergy or Hypersensitivity to Indomethacin, Probenecid, or any other NSAID (e.g., aspirin), especially those with a history of asthma, hives, or allergic-type reactions to NSAIDs.
• Active gastrointestinal ulceration, inflammation, or bleeding.
• Severe heart failure or recent coronary artery bypass graft (CABG) surgery.
• Severe kidney disease or those with uric acid kidney stones.
• Certain blood disorders (blood dyscrasias).
• Pregnancy (especially in the third trimester) and breastfeeding, due to potential risks to the fetus or infant.
• Children under 2 years old.

Interactions with Other Medicines and Products

Индоксил (Indoxyl) is often used as a reference to its sulfate form, Indoxyl Sulfate (IS), a uremic toxin that accumulates in patients with impaired kidney function. While Индоксил is not a pharmaceutical drug itself, its accumulation in the body can significantly impact the pharmacokinetics of many prescription medications by interfering with key processes, primarily drug transport and metabolism.

Drug-Drug Interactions

Indoxyl Sulfate is highly protein-bound, predominantly to albumin. This high binding can affect the distribution of other highly protein-bound drugs, potentially altering their free (active) concentration and increasing the risk of toxicity. IS also competes with many drugs for transport via Organic Anion Transporters (OAT1 and OAT3) in the kidneys. Medications that share these same transport pathways may have reduced renal clearance, leading to elevated drug levels in the bloodstream. Examples include:

• Diuretics: Drugs like furosemide may have reduced effectiveness, and the combination may also worsen IS accumulation.
• Antihypertensives: Certain agents, such as valsartan and losartan, may have altered clearance due to competition for OAT transporters.
• Other highly protein-bound drugs: The free concentration of drugs like warfarin may be affected, requiring close monitoring.

IS may also influence the activity of drug-metabolizing enzymes, such as certain Cytochrome P450 (CYP) enzymes, which can alter the metabolism and efficacy of numerous co-administered drugs. Patients with chronic kidney disease and high IS levels should have all medications reviewed carefully by a healthcare professional.

How Индоксил Works

---

Dual-Pathway Antimicrobial Action and Bacterial Control

This mechanistic domain centers on the combined anti-pathogen strategies of the active ingredients. Clindamycin works by selectively inhibiting the bacterial ribosome (specifically the 50S subunit), blocking the synthesis of proteins required for Cutibacterium acnes growth, resulting in a bacteriostatic effect. Simultaneously, Benzoyl Peroxide generates free radicals that cause non-specific oxidative destruction of bacterial structures, providing a rapid bactericidal effect. This concerted effort leads to a reduction in the overall C. acnes population.

Keratolytic Modulation of Follicular Clearance

The second key domain focuses on the physical action of Benzoyl Peroxide within the skin's pilosebaceous unit. This compound exerts a keratolytic effect, meaning it modulates the abnormal adhesion of keratinocytes (skin cells) lining the follicular canal. This mechanism promotes the shedding and desquamation of these cells, which is the physiological process that facilitates the clearance of the follicular obstruction.

Mechanistic Synergy Against Resistance and Inflammation

The combination employs a critical anti-resistance synergy, where the non-specific, oxidative mechanism of Benzoyl Peroxide suppresses the emergence of C. acnes strains that are resistant to Clindamycin, which supports the preservation of antibiotic susceptibility to Clindamycin. Furthermore, the combined agents reduce local inflammatory mediators (like pro-inflammatory cytokines), which modulates the localized immune response.

How to Use Индоксил

This section details the usage patterns and administration guidelines for Индоксил (Clindamycin Phosphate and Benzoyl Peroxide Topical Gel). The following are the established usage patterns for this formulation.

---

Administration Scope

Category	Application Detail
Route of administration	Topical (Dermatological Use Only). Not for ophthalmic, oral, or intravaginal application.
Dosing schedule	Apply a pea-sized amount or thin layer sufficient to cover the entire affected area.
Frequency and timing	Typically applied Once Daily (often in the evening), though some formulations may be used Twice Daily.
Pre-Application Condition	The skin must be gently washed with a mild cleanser and patted dry before use.
Age-group rules	Approved for use in patients 12 years of age and older. Safety and efficacy are not established in children under 12 years of age.
Duration constraint	Continuous use has not been evaluated beyond 12 weeks.

---

Resulting Procedural Structure

The protocol follows a specific sequence for application. First, the application site must be cleaned and dried. A minimal amount of the gel is then to be applied to the entire affected area, ensuring the product rubs into the skin easily. Application must strictly avoid contact with all mucous membranes (eyes, mouth, lips, nose) and broken skin. This protocol ensures the drug is used via the approved topical route and within evaluated timeframes.

Research Evidence / Overview of Studies for Индоксил

Evidence for use in Acne Vulgaris

The core of the research for this combination gel was evaluated in Randomized Controlled Trials (RCTs). These pivotal trials were applied in studies examining patient-reported experiences and exploring how symptoms change over time in individuals with Acne Vulgaris, a condition characterized by fluctuating or episodic manifestations. The RCTs were often structured to compare the combination gel against a non-medicated vehicle (placebo) and the individual active ingredients (Clindamycin alone or Benzoyl Peroxide alone). Research explored outcomes related to physical discomfort, tracking changes in lesion counts (inflammatory and non-inflammatory blemishes) and overall skin appearance using standardized grading scales.

Findings describe patterns observed in the studies, including measured changes in lesion counts and the proportion of observed populations who reached specific low-severity ratings. Research also examined microbiological outcomes, such as the counts of Cutibacterium acnes bacteria and the development of antibiotic resistance when the components were observed together.

---

Long-term Studies and Follow-up

The main efficacy trials for the combination gel primarily focused on intermediate-term observation. Research examined short-term symptom changes, with primary assessment data documented over a defined time interval of typically 10 to 12 weeks. While this observation period was used in research exploring how symptoms change over time for regulatory submission, there is limited information for long-term outcomes.

Specifically, long-term effects are not fully established regarding the durability of observed changes or the need for sustained use. Follow-up durations were limited, and the data are still emerging regarding patterns that may occur after the initial three months of use.

---

Research Gaps and Areas of Uncertainty

Certainty remains low in several areas because the available research has specific boundaries. One of the key research limitation frames is that long-term effects are not fully established. Comparative evidence is lacking against certain other currently available standard treatments. Furthermore, evidence quality varies across studies, and findings were mixed in some meta-analyses due to heterogeneity (differences in study designs and populations). Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

1. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel: Full Prescribing Information (FDA Labeling)
2. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne
3. Fixed-Combination Therapy for Moderate to Severe Acne: A Review of Clindamycin Phosphate 1.2%–Benzoyl Peroxide 2.5% Gel

Common questions about Индоксил (FAQ)

Q: Индоксил — это антибиотик, обезболивающее или что-то другое? (Is Индоксил an antibiotic, a painkiller, or something else?)

A: Индоксил (Indoxyl) Topical Gel is classified as a combination product for acne treatment. It contains two active ingredients: Clindamycin, which is an antibiotic, and Benzoyl Peroxide, which has antiseptic and skin-shedding properties. Official information indicates it is not primarily categorized as a painkiller (analgesic).

Q: Какие самые частые побочные эффекты бывают от Индоксила? (What are the most common side effects of Индоксил?)

A: According to official product information, the most common side effects are local skin reactions. These frequently include redness (erythema), dry skin, and peeling (exfoliation). These reactions are typically most noticeable at the beginning of treatment.

Q: Чем Индоксил отличается от других популярных НПВП (Нестероидных противовоспалительных препаратов)? (How does Индоксил differ from other popular NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)?)

A: The topical gel formulation of Индоксил is an anti-acne agent applied to the skin. Unlike systemic NSAIDs, which work by blocking inflammation-causing enzymes in the body, this gel targets bacteria and promotes skin shedding. It is classified differently from Nonsteroidal Anti-Inflammatory Drugs.

Q: Что делать, если пропустил прием Индоксила? (What should I do if I missed a dose of Индоксил?)

A: Official patient information outlines what to do if an application is missed. Generally, if remembered soon after, the missed dose can be applied. If it is almost time for the next scheduled application, the missed dose is typically skipped, and the regular schedule is resumed. Consult the specific patient leaflet for detailed guidance.

Q: Индоксил нужно принимать до еды, во время или после? (Should Индоксил be taken before, during, or after food?)

A: Индоксил is a topical gel that is applied only to the skin and is not taken orally (by mouth). Therefore, the timing of application is not related to meals or food intake.

Q: Может ли Индоксил вызвать аллергическую реакцию? (Can Индоксил cause an allergic reaction?)

A: Yes, regulatory documents note that hypersensitivity reactions (a type of allergic reaction) have been reported. The product is strictly contraindicated for anyone with a known allergy to either Clindamycin, Benzoyl Peroxide, or the related antibiotic Lincomycin.

Q: Есть ли научные исследования, подтверждающие эффективность Индоксила при [конкретном заболевании]? (Are there scientific studies confirming the effectiveness of Индоксил for [specific condition]?)

A: Yes, the effectiveness of the gel has been confirmed by randomized controlled trials (RCTs). These studies specifically focused on its use for treating mild to moderate Acne Vulgaris.

Q: Что означает, что Индоксил является 'ингибитором ЦОГ-1 и ЦОГ-2'? (What does it mean that Индоксил является 'COX-1 and COX-2 inhibitor'?)

A: This description refers to the oral product containing the active ingredient Indomethacin, which is used for conditions like arthritis and gout. It means the drug works by blocking Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. Blocking these enzymes reduces the body's production of chemicals that cause inflammation and pain.

Q: Почему Индоксил не рекомендуют пожилым людям? (Why is Индоксил not recommended for elderly people?)

A: The oral (non-topical) version containing the NSAID Indomethacin may require caution in elderly patients. This is because older adults can be more sensitive to systemic side effects, such as potential issues with the kidneys or stomach, and requires careful medical supervision.

Q: Через какое время после начала применения можно заметить эффект от Индоксила? (How long after starting use can the effect from Индоксил be noticed?)

A: Clinical studies for the topical gel formulation track effectiveness over time. They specifically show a decrease in acne lesions by the end of Week 12, which is the time of maximum observed efficacy. Some patients may notice improvement earlier than this period.

Q: Можно ли принимать Индоксил, если у меня проблемы с желудком, например гастрит? (Can I take Индоксил if I have stomach problems, such as gastritis?)

A: For the topical gel, regulatory documents list a history of certain severe intestinal inflammatory conditions (like colitis) as a contraindication. While the low systemic absorption of the gel makes stomach irritation less likely, individuals with existing upper gastrointestinal problems like gastritis need to clarify their situation with a healthcare professional.

Q: Влияет ли Индоксил на работу почек или печени? (Does Индоксил affect kidney or liver function?)

A: Systemic exposure to the topical gel is minimal, so it is not expected to significantly affect the liver or kidneys. However, the antibiotic component, Clindamycin, when administered orally, has been rarely associated with liver enzyme elevations and acute kidney injury that usually resolve after stopping the medicine.

Q: Правда ли, что Индоксил может повышать риск проблем с сердцем? (Is it true that Индоксил can increase the risk of heart problems?)

A: The oral product containing the NSAID Indomethacin, like other drugs in that class, carries a warning about a potential increased risk of serious cardiovascular issues. These issues include heart attack, stroke, and related events, particularly with prolonged use.

Q: С чем Индоксил нельзя принимать одновременно? (What should Индоксил not be taken with simultaneously?)

A: When using the topical gel, official information recommends avoiding the simultaneous use of other topical acne treatments unless specifically directed by a healthcare professional. Caution is also advised regarding combining it with other products containing Clindamycin or Erythromycin.

Q: Разрешено ли употреблять алкоголь во время лечения Индоксилом? (Is it allowed to consume alcohol while being treated with Индоксил?)

A: For the topical gel, which is applied to the skin, no interaction with alcohol is expected. However, for the oral (non-topical) product containing Indomethacin, alcohol consumption should generally be avoided due to the potential for an increased risk of gastrointestinal bleeding.

Q: Почему во время приема Индоксила важно следить за кровяным давлением? (Why is it important to monitor blood pressure while taking Индоксил?)

A: This warning relates to the oral product containing the NSAID Indomethacin. NSAIDs may reduce the effectiveness of certain blood pressure medications (antihypertensives). They may also cause fluid retention or lead to new or worsened high blood pressure.

Q: Что делать, если при приеме Индоксила появились черные испражнения? (What should I do if I notice black stools while taking Индоксил?)

A: Black stools (melena) can be a serious sign of internal bleeding, which is a known risk for the oral NSAID (Indomethacin) product. If this sign appears, stopping the medication and seeking immediate medical attention is necessary due to the potential for serious internal bleeding.

Q: Можно ли принимать Индоксил одновременно с лекарствами для разжижения крови (антикоагулянтами)? (Can I take Индоксил simultaneously with blood thinners (anticoagulants)?)

A: The oral product containing Indomethacin interacts with blood thinners, such as Warfarin, creating a significantly increased risk of serious bleeding. This combination must only be used under close medical monitoring.

Q: Как долго обычно длится курс лечения Индоксилом? (How long does the course of treatment with Индоксил usually last?)

A: The length of treatment is decided by a healthcare provider. For the topical gel, clinical trials that established its effectiveness were limited to a duration of 12 continuous weeks. Safety and effectiveness beyond this period are not fully established.

Q: Почему Индоксил может вызвать звон в ушах? (Why can Индоксил cause ringing in the ears?)

A: Ringing in the ears (tinnitus) is a potential, but less common, side effect associated with the oral NSAID (Indomethacin) product. This effect is thought to be related to the drug's impact on the auditory system.

Q: Если у меня астма, можно ли мне принимать Индоксил? (If I have asthma, can I take Индоксил?)

A: Patients with asthma should use the oral (non-topical) version containing Indomethacin with caution. Regulatory documents advise monitoring, as this NSAID can sometimes worsen asthma symptoms, especially in individuals with aspirin sensitivity.

Q: Индоксил только для суставов или его используют и для других видов боли? (Is Индоксил only for joints, or is it used for other types of pain as well?)

A: The oral (non-topical) version containing Indomethacin is approved for treating inflammatory joint conditions, such as arthritis. Additionally, it is also approved for treating other types of acute pain, including tendinitis and bursitis.

Q: Может ли Индоксил повлиять на результаты анализов крови? (Can Индоксил affect blood test results?)

A: Yes, the oral (non-topical) version containing Indomethacin can potentially affect the body's blood-forming systems. Regulatory information notes it can cause changes in certain blood cell counts, such as anemia, which could be observed in routine blood tests.

Q: Что может увеличить риск развития язвы желудка при приеме Индоксила? (What can increase the risk of developing a stomach ulcer when taking Индоксил?)

A: For the oral (non-topical) version containing Indomethacin, risk factors for developing stomach ulcers include long-term use, a prior history of ulcers, and simultaneous use of alcohol, oral corticosteroids, or blood thinners.

Q: Влияет ли Индоксил на способность управлять автомобилем? (Does Индоксил affect the ability to drive?)

A: The topical gel is not expected to have any known or anticipated effect on a person's ability to drive or operate machinery, as stated in the official product information.

Q: Может ли Индоксил использоваться для снижения высокой температуры (лихорадки)? (Can Индоксил be used to reduce high fever?)

A: The oral (non-topical) version of Индоксил contains Indomethacin, which is a Nonsteroidal Anti-Inflammatory Drug (NSAID). This class of drugs has established antipyretic (fever-reducing) properties.

Q: Какие признаки могут указывать на передозировку Индоксилом? (What signs might indicate an overdose of Индоксилом?)

A: In case of oral overdose, serious signs can include severe headache, mental confusion, nausea, vomiting, and, rarely, seizures. Topical overdose on the skin may primarily result in excessive redness, peeling, and skin irritation.

Q: Как Индоксил влияет на головную боль? (How does Индоксил affect headaches?)

A: Headache is listed in the official documents as a common adverse reaction for both the topical gel and the oral (non-topical) formulation.

Q: Можно ли Индоксил сочетать с местными обезболивающими кремами или гелями? (Can Индоксил be combined with topical pain relief creams or gels?)

A: Regarding the topical gel for acne, official documents generally advise against applying it at the same time as other topical products unless directed by a healthcare professional, due to the increased risk of skin irritation.

Q: Почему при использовании геля Индоксил может появиться сухость или шелушение кожи? (Why might skin dryness or peeling occur when using Индоксил gel?)

A: The Benzoyl Peroxide ingredient is included for its keratolytic action, which is the process of causing the skin cells to shed. This intended mechanism of action directly leads to the very common side effects of dryness and peeling (exfoliation).

Q: В чем разница между применением Индоксила в капсулах и в виде геля? (What is the difference between using Индоксил в капсулах and in виде геля?)

A: The gel is a topical formulation containing Clindamycin and Benzoyl Peroxide for treating acne on the skin's surface. The capsule/oral form contains Indomethacin and Probenecid and is taken by mouth for systemic conditions like arthritis and gout.

Q: Может ли Индоксил взаимодействовать с лекарствами от давления? (Can Индоксил interact with blood pressure medications?)

A: Yes, regulatory documents for the oral (non-topical) product containing Indomethacin indicate that it can interact with certain antihypertensive drugs. This can reduce the effectiveness of the blood pressure medication.

Q: При каких заболеваниях суставов Индоксил наиболее эффективен? (For which joint diseases is Индоксил most effective?)

A: The oral (non-topical) product is indicated for treating inflammatory joint conditions. Specifically, its use is approved for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute gouty arthritis.

Q: Что известно о резистентности к антибиотику в составе Индоксила (для геля)? (What is known about antibiotic resistance to the component in Индоксила (для геля)?)

A: The inclusion of Benzoyl Peroxide in the topical gel is a key part of the treatment strategy. Official information indicates that Benzoyl Peroxide's non-specific action helps suppress the development of bacterial resistance to the antibiotic Clindamycin component.

Q: Может ли Индоксил вызывать тревожность или изменение настроения? (Can Индоксил cause anxiety or mood changes?)

A: The oral (non-topical) product containing Indomethacin is associated with central nervous system (CNS) side effects. These can include reported adverse reactions such as depression or confusion, which may present as changes in mood.

Q: Почему в инструкции к Индоксилу упоминаются судороги? (Why are seizures mentioned in the instructions for Индоксилу?)

A: Seizures are mentioned in the regulatory documents as a potential symptom of acute overdose of the oral product containing the NSAID Indomethacin.

Q: Какое влияние Индоксил оказывает на слизистые оболочки? (What effect Индоксил has on mucous membranes?)

A: Official administration instructions for the topical gel strongly emphasize that contact with mucous membranes, such as the eyes, nose, lips, and mouth, must be strictly avoided. In case of accidental contact, the area should be rinsed thoroughly with water.

Q: Почему Индоксил назначают при подагре? (Why is Индоксил prescribed for gout?)

A: The oral (non-topical) version is prescribed for acute gouty arthritis because it contains two key active ingredients. Indomethacin provides strong anti-inflammatory relief, and Probenecid works to help the body excrete excess uric acid, which is the underlying cause of gout.

How to Store and Dispose of Индоксил (Clindamycin Phosphate and Benzoyl Peroxide Gel)

Official labeling mandates specific storage for this combination gel. Prior to dispensing, the product components require refrigerated storage between 2 C and 8 C. After the product is mixed and dispensed, it must be stored at room temperature, up to 25 C, and must not be frozen.

Stability and Safety

Condition	Requirement
Stability Period	Discard unused product after 2 or 3 months post-dispensing, as specified by the label.
Container	Keep the original container tightly closed and away from excess heat and moisture.
Handling Precaution	The gel may bleach hair or colored fabric.
Child Safety	Keep out of the sight and reach of children.

Unused or expired gel must be properly discarded; consult a healthcare professional for local disposal regulations.